Clinical Trials in Portugal

• Pembrolizumab with Lenvatinib versus Docetaxel for Metastatic NSCLC after Platinum Doublet Chemotherapy and Immunotherapy Ended
  2022-501439-18-00 Phase III NSCLC with squamous or nonsquamous histology Merck Sharp & Dohme LLC
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 Phase III Adults at high risk of cardiovascular events without prior M… Amgen Inc.
• A study evaluating the efficacy and safety of ralinepag in treatment of patients with pulmonary arterial hypertension. Ended
  2023-509304-16-00 Phase III Pulmonary arterial hypertension (PAH) United Therapeutics Corp.
• HELIOS-A: A Phase 3 Global Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis Ended
  2023-508365-33-00 Phase III Hereditary Transthyretin Amyloidosis Alnylam Pharmaceuticals Inc.
• A safety and efficacy study of ABT-494 in subjects with Giant Cell Arteritis. Ended
  2023-505476-29-00 Phase III Giant Cell Arteritis AbbVie Deutschland GmbH & Co. KG
• Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC Ended
  2022-500395-57-00 Phase III Resectable high-risk Locally Advanced Cutaneous Squamous Cel… Merck Sharp & Dohme Corp.
• Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema) – Measure Up 2 Ended
  2022-502936-38-00 Phase III Moderate and Severe Atopic Dermatitis Abbvie Deutschland GmbH & Co. KG
• Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended
  2023-505494-32-00 Phase III Focal segmental glomerulosclerosis (FSGS) Travere Therapeutics Inc.
• Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease Ended
  2024-511553-22-00 Phase III Moderately to Severely Active Crohn's Disease Celgene International II SARL
• A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelia… Ended
  2024-517571-20-00 Phase III Locally advanced or metastatic urothelial cancer Astellas Pharma Global Development Inc.
• A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la … Ended
  2023-506543-41-00 Phase III Multiple sclerosis (MS) F. Hoffmann-La Roche AG
• A Phase 3 randomized clinical Study of Pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen as first line trea… Ended
  2024-512015-47-00 Phase III Histologically or cytologically-confirmed Recurrent or Metas… Incyte Corp.
• A multicenter, open-label, randomized study with single-arm extension period to assess the pharmacokinetics, safety and efficacy of macitent… Ended
  2023-509845-10-00 Phase III Pediatric pulmonary arterial hypertension Actelion Pharmaceuticals Ltd.
• A study of Ibrutinib in combination with Rituximab versus Placebo in combination with Rituximab in treatment of patients with Follicular Lym… Ended
  2023-507271-21-00 Phase III Follicular Lymphoma AbbVie Deutschland GmbH & Co. KG
• A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy … Ended
  2022-501382-49-00 Phase III Triple Negative Breast Cancer (TNBC) Merck Sharp & Dohme LLC
• autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea… Ended
  2024-511235-10-00 Phase III Generalized mantle cell Lymphoma Klinikum der Universitaet Muenchen AöR
• "A study to learn how well the drug larotrectinib works in adults with different solid cancers with a change in the genes called NTRK fusion… Ended
  2022-502667-38-00 Phase II Solid tumors harboring NTRK fusion Bayer AG; Bayer Consumer Care AG
• A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af… Ended
  2023-509137-39-00 Phase III Stage IB (T ≥ 4 cm), II and IIIA NSCLC Merck Sharp & Dohme LLC
• A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Parti… Ended
  2023-506859-13-00 Phase III Anaplastic lymphoma kinase (ALK)-positive non-small cell lun… F. Hoffmann-La Roche AG
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in … Ended
  2022-500691-59-00 Phase II Alzheimer's disease (AD) Abbvie Deutschland GmbH & Co. KG
• A trial to learn if andexanet alfa is safe and works to limit bleeding in people who take factor 10a inhibitors and urgently need surgery Ended
  2022-501353-37-00 Phase III Reversal of anticoagulation effect in patients on a FXa inhi… Astrazeneca AB
• Bioequivalence of Eltrombopag 25 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions. Ended
  2023-504468-41-00 No medical condition Bluepharma Industria Farmaceutica S.A.
• Comparative Bioavailability of Diclofenac 2.32% Gel in Healthy Adult Subjects Ended
  2023-507428-21-00 No medical condition. Alkaloid AD Skopje
• A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Ref… Ended
  2023-509472-42-00 Phase III Relapsed and/or Refractory Multiple Myeloma Celgene International II S.a.r.l.

Showing 841–864 of 866 trials